Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma - real-life data from a national multicenter observational study.

Shimony S, Horowitz N, Ribakovsky E, Rozovski U, Avigdor A, Zloto K, Berger T, Avivi I, Perry C, Abadi U, Raanani P, Gafter-Gvili A, Gurion R.

Hematol Oncol. 2019 Oct 31. doi: 10.1002/hon.2691. [Epub ahead of print]


Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.

Zlotnick M, Avigdor A, Ribakovsky E, Nagler A, Kedmi M.

Acta Haematol. 2019;141(2):84-90. doi: 10.1159/000495283. Epub 2019 Jan 10.


The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.

Beider K, Rosenberg E, Bitner H, Shimoni A, Leiba M, Koren-Michowitz M, Ribakovsky E, Klein S, Olam D, Weiss L, Wald H, Abraham M, Galun E, Peled A, Nagler A.

Clin Cancer Res. 2017 Apr 1;23(7):1733-1747. doi: 10.1158/1078-0432.CCR-15-2618. Epub 2016 Oct 3.


Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects.

Simon AJ, Lev A, Zhang Y, Weiss B, Rylova A, Eyal E, Kol N, Barel O, Cesarkas K, Soudack M, Greenberg-Kushnir N, Rhodes M, Wiest DL, Schiby G, Barshack I, Katz S, Pras E, Poran H, Reznik-Wolf H, Ribakovsky E, Simon C, Hazou W, Sidi Y, Lahad A, Katzir H, Sagie S, Aqeilan HA, Glousker G, Amariglio N, Tzfati Y, Selig S, Rechavi G, Somech R.

J Exp Med. 2016 Jul 25;213(8):1429-40. doi: 10.1084/jem.20151618. Epub 2016 Jul 18.


Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.

Gafter-Gvili A, Ribakovsky E, Mizrahi N, Avigdor A, Aviv A, Vidal L, Ram R, Perry C, Avivi I, Kedmi M, Nagler A, Raanani P, Gurion R.

Leuk Lymphoma. 2016;57(1):63-9. doi: 10.3109/10428194.2015.1046862. Epub 2015 May 25.


Autologous transplantation and maintenance therapy in multiple myeloma.

Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M.

N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888.


Outcome differences in patients with precursor B cell acute lymphocytic leukemia over time: a retrospective analysis.

Apel A, Kedmi M, Levi E, Berkowicz M, Davidovitz Y, Kneller A, Ribakovsky E, Shimoni A, Nagler A, Avigdor A.

Isr Med Assoc J. 2014 Apr;16(4):224-8.


Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?

Kedmi M, Avivi I, Ribakovsky E, Benyamini N, Davidson T, Goshen E, Tadmor T, Nagler A, Avigdor A.

Leuk Lymphoma. 2014 Nov;55(11):2484-9. doi: 10.3109/10428194.2014.882506. Epub 2014 Mar 7.


OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.

Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, Shimoni A, Beider K, Amariglio N, le Coutre P, Nagler A.

Eur J Haematol. 2014 Apr;92(4):283-8. doi: 10.1111/ejh.12235. Epub 2013 Dec 18.


Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.

Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L, Rosenberg E, Galun E, Avigdor A, Eizenberg O, Peled A, Nagler A.

Clin Cancer Res. 2013 Jul 1;19(13):3495-507. doi: 10.1158/1078-0432.CCR-12-3015. Epub 2013 May 1.


Recombinant human erythropoietin attenuates hepatic injury induced by ischemia/reperfusion in an isolated mouse liver model.

Hochhauser E, Pappo O, Ribakovsky E, Ravid A, Kurtzwald E, Cheporko Y, Lelchuk S, Ben-Ari Z.

Apoptosis. 2008 Jan;13(1):77-86.


Supplemental Content

Loading ...
Support Center